Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Dec 10, 2024, 07:30 ET Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…
Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology NEWS PROVIDED BY Alphyn Biologics Nov 01, 2024, 07:30 ET Paper highlights Zabalafin Hydrogel’s potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/…
Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 NEWS PROVIDED BY Alphyn Biologics Aug 27, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 27, 2024 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that data from its Phase 2a human clinical…
Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics Aug 21, 2024, 07:30 ET ANNAPOLIS, Md., Aug. 21, 2024 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that it has received a notice of claims allowance from the U.S. Patent and Trademark…
Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 07, 2024, 07:30 ET All endpoints met Significant improvements in itch and quality of life Significant control of staph bacteria-associated and other AD flares Clearance of infected AD skin Significant improvements in inflammation ANNAPOLIS,…